Back
About
The company is a clinical biopharmaceutical firm developing MET-097i as an injectable treatment for obesity in a Phase I/Phase 2 clinical trial involving overweight or obese healthy volunteers. Incorporated in Delaware, the company is focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.
Obesity and overweight are among the fastest-growing and most prevalent chronic human conditions, affecting approximately 2.5 billion people worldwide and contributing to a broad range of severe diseases. Currently approved NuSH analog peptides represent a promising treatment option for these conditions. The company utilizes its proprietary MINT peptide library of NuSH analog peptides, along with its Half-life Augmentation by Lipid Optimization (HALO) half-life extending platform and MOMENTUM oral NuSH analog peptide delivery platform, to develop highly differentiated product candidates. These candidates are being advanced into clinical trials for obesity and overweight treatment.
Headquarters
3 World Trade Center 175 Greenwich Street New York, New York
Team
Whit Bernard - Co-founder, Chief Executive Officer and President,
Steve Bloom - EVP of Research & Development, Founder and Former Executive Chairman, Zihipp
Financial information
Underwriters
BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, Cantor
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.